Metraipolis › archive › dc_cd0fd0bac890
Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma — Europe PMC PMID:31905218
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/31905218
- DOI
- 10.1371/journal.ppat.1008223
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-09T18:51:12.997Z
- SHA-256 of the archived text
9b3a7a46873c1a04e9804b954d54008d049cd0c0ace747338217b912a7a33ad8- Stable URL of this page
https://metraipolis.com/documento/dc_cd0fd0bac890
How to cite
Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma — Europe PMC PMID:31905218 — Europe PMC (en), https://europepmc.org/article/MED/31905218 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_cd0fd0bac890 (Metraipolis archive dc_cd0fd0bac890, sha256 9b3a7a46873c1a04e9804b954d54008d049cd0c0ace747338217b912a7a33ad8)
BibTeX
@misc{dccd0fd0bac890,
title = {Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma — Europe PMC PMID:31905218},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/31905218},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_cd0fd0bac890; sha256 9b3a7a46873c1a04e9804b954d54008d049cd0c0ace747338217b912a7a33ad8},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/31905218. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Epstein-Barr virus (EBV) infection is closely linked to several human malignancies including endemic Burkitt's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinomas (NPC). Latent membrane protein 2 (LMP-2) of EBV plays a pivotal role in pathogenesis of EBV-related tumors and thus, is a potential target for diagnosis and targeted therapy of EBV LMP-2+ malignant cancers. Affibody molecules are developing as imaging probes and tumor-targeted delivery of small molecules. In this study, four EBV LMP-2-binding affibodies (ZEBV LMP-212, ZEBV LMP-2132, ZEBV LMP-2137, and ZEBV LMP-2142) were identified by screening a phage-displayed LMP-2 peptide library for molecular imaging and targeted therapy in EBV xenograft mice model. ZEBV LMP-2 affibody has high binding affinity for EBV LMP-2 and accumulates in mouse tumor derived from EBV LMP-2+ xenografts for 24 h after intravenous (IV) injection. Subsequent fusion of Pseudomonas exotoxin PE38KDEL to the ZEBV LMP-2 142 affibody led to production of Z142X affitoxin. This fused Z142X affitoxin exhibits high cytotoxicity specific for EBV+ cells in vitro and significant antitumor effect in mice bearing EBV+ tumor xenografts by IV injection. The data provide the proof of principle that EBV LMP-2-speicifc affibody molecules are useful for molecular imaging diagnosis and have potentials for targeted therapy of LMP-2-expressing EBV malignancies. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS pathogens, 2020 (prima pubblicazione 2020-01-06). Identificativi: PMID 31905218 · PMCID PMC6964910 · DOI 10.1371/journal.ppat.1008223. Descrittori MeSH principali: Herpesvirus 4, Human. Pagina: https://europepmc.org/article/MED/31905218 — https://doi.org/10.1371/journal.ppat.1008223. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-09T18:47:45.671Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.